Dynavax Technologies Investor Deep Track Capital Nominates 4 Independent Directors

MT Newswires Live

Feb 19, 2025

Dynavax Technologies' (DVAX) shareholder Deep Track Capital nominated four independent directors to the biopharmaceutical company's board to focus on key hepatitis B vaccine Heplisav and shift away from acquisitions.

"Focusing on Heplisav could result in nearly $2 billion of cash being returned to shareholders by the end of 2030," Deep Track Capital said Wednesday in a statement. The investment firm said it owns 13.53% of Dynavax.

A Deep Track letter to Dynavax shareholders criticized the biopharmaceutical company's board's "poor governance, reactive entrenchment maneuvers and unwillingness to work constructively."

Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel were nominated as Dynavax directors, Deep Track said.

Dynavax didn't immediately respond to a request for comment from MT Newswires.

Shares of the company rose 3.1% in recent trading.

Price: 13.33, Change: +0.40, Percent Change: +3.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2512892134"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512892134\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512892134?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-19 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512892134","market":"fut","top_or_hot":-1,"title":"Dynavax Technologies Investor Deep Track Capital Nominates 4 Independent Directors","media":"MT Newswires Live","content":"<html><body><p> Dynavax Technologies' (DVAX) shareholder Deep Track Capital nominated four independent directors to the biopharmaceutical company's board to focus on key hepatitis B vaccine Heplisav and shift away from acquisitions.</p><p>\"Focusing on Heplisav could result in nearly $2 billion of cash being returned to shareholders by the end of 2030,\" Deep Track Capital said Wednesday in a statement. The investment firm said it owns 13.53% of Dynavax.</p><p>A Deep Track letter to Dynavax shareholders criticized the biopharmaceutical company's board's \"poor governance, reactive entrenchment maneuvers and unwillingness to work constructively.\"</p><p>Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel were nominated as Dynavax directors, Deep Track said.</p><p>Dynavax didn't immediately respond to a request for comment from MT Newswires.</p><p>Shares of the company rose 3.1% in recent trading.</p><p>Price: 13.33, Change: +0.40, Percent Change: +3.09</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dynavax Technologies Investor Deep Track Capital Nominates 4 Independent Directors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDynavax Technologies Investor Deep Track Capital Nominates 4 Independent Directors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-19 23:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dynavax Technologies' (DVAX) shareholder Deep Track Capital nominated four independent directors to the biopharmaceutical company's board to focus on key hepatitis B vaccine Heplisav and shift away from acquisitions.</p><p>\"Focusing on Heplisav could result in nearly $2 billion of cash being returned to shareholders by the end of 2030,\" Deep Track Capital said Wednesday in a statement. The investment firm said it owns 13.53% of Dynavax.</p><p>A Deep Track letter to Dynavax shareholders criticized the biopharmaceutical company's board's \"poor governance, reactive entrenchment maneuvers and unwillingness to work constructively.\"</p><p>Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel were nominated as Dynavax directors, Deep Track said.</p><p>Dynavax didn't immediately respond to a request for comment from MT Newswires.</p><p>Shares of the company rose 3.1% in recent trading.</p><p>Price: 13.33, Change: +0.40, Percent Change: +3.09</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVAX","symbol_name":"德纳维制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2512892134","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512892134","pubTimestamp":1739980277,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dynavax Technologies'  shareholder Deep Track Capital nominated four independent directors to the biopharmaceutical company's board to focus on key hepatitis B vaccine Heplisav and shift away from acquisitions.\"Focusing on Heplisav could result in nearly $2 billion of cash being returned to shareholders by the end of 2030,\" Deep Track Capital said Wednesday in a statement. The investment firm said it owns 13.53% of Dynavax.A Deep Track letter to Dynavax shareholders criticized the biopharmaceutical company's board's \"poor governance, reactive entrenchment maneuvers and unwillingness to work constructively.\"Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel were nominated as Dynavax directors, Deep Track said.Dynavax didn't immediately respond to a request for comment from MT Newswires.Shares of the company rose 3.1% in recent trading.Price: 13.33, Change: +0.40, Percent Change: +3.09","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVAX":"德纳维制药","BK4139":"生物科技"},"translate_title":"Dynavax Technologies投资者Deep Track Capital提名4名独立董事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVAX":1},"content_text":"Dynavax Technologies' (DVAX) shareholder Deep Track Capital nominated four independent directors to the biopharmaceutical company's board to focus on key hepatitis B vaccine Heplisav and shift away from acquisitions.\"Focusing on Heplisav could result in nearly $2 billion of cash being returned to shareholders by the end of 2030,\" Deep Track Capital said Wednesday in a statement. The investment firm said it owns 13.53% of Dynavax.A Deep Track letter to Dynavax shareholders criticized the biopharmaceutical company's board's \"poor governance, reactive entrenchment maneuvers and unwillingness to work constructively.\"Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel were nominated as Dynavax directors, Deep Track said.Dynavax didn't immediately respond to a request for comment from MT Newswires.Shares of the company rose 3.1% in recent trading.Price: 13.33, Change: +0.40, Percent Change: +3.09","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}